Pegasus Partners Ltd. lessened its stake in EXACT Sciences Co. (NASDAQ:EXAS) by 41.2% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,475 shares of the medical research company’s stock after selling 10,825 shares during the quarter. Pegasus Partners Ltd.’s holdings in EXACT Sciences were worth $813,000 at the end of the most recent reporting period.
Other institutional investors also recently added to or reduced their stakes in the company. C M Bidwell & Associates Ltd. acquired a new position in shares of EXACT Sciences in the fourth quarter valued at approximately $117,000. Crow Point Partners LLC acquired a new position in shares of EXACT Sciences in the fourth quarter valued at approximately $145,000. Oppenheimer Asset Management Inc. boosted its holdings in shares of EXACT Sciences by 2,925.7% in the third quarter. Oppenheimer Asset Management Inc. now owns 3,177 shares of the medical research company’s stock valued at $150,000 after buying an additional 3,072 shares during the period. SG Americas Securities LLC acquired a new position in shares of EXACT Sciences in the third quarter valued at approximately $183,000. Finally, Crescent Grove Advisors LLC acquired a new position in shares of EXACT Sciences in the third quarter valued at approximately $200,000. Institutional investors own 83.12% of the company’s stock.
Several research analysts have recently weighed in on EXAS shares. Bank of America set a $56.00 price target on shares of EXACT Sciences and gave the company a “buy” rating in a report on Thursday, October 19th. Jefferies Group upped their price target on shares of EXACT Sciences to $60.00 and gave the company a “buy” rating in a report on Tuesday, October 31st. Leerink Swann reiterated an “outperform” rating and issued a $63.00 price target (up previously from $50.00) on shares of EXACT Sciences in a report on Tuesday, October 31st. Benchmark restated a “buy” rating and set a $60.00 target price (up previously from $50.00) on shares of EXACT Sciences in a report on Tuesday, October 31st. Finally, Craig Hallum increased their target price on shares of EXACT Sciences from $46.00 to $61.00 and gave the stock a “buy” rating in a report on Tuesday, October 31st. Eight investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $52.84.
In other EXACT Sciences news, insider Kevin T. Conroy sold 110,439 shares of the stock in a transaction on Tuesday, January 23rd. The shares were sold at an average price of $50.49, for a total value of $5,576,065.11. Following the completion of the sale, the insider now owns 940,491 shares in the company, valued at $47,485,390.59. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Kevin T. Conroy sold 101,488 shares of the stock in a transaction on Friday, February 9th. The shares were sold at an average price of $45.72, for a total transaction of $4,640,031.36. Following the completion of the sale, the insider now owns 931,540 shares of the company’s stock, valued at approximately $42,590,008.80. The disclosure for this sale can be found here. Insiders have sold 764,182 shares of company stock valued at $40,574,047 in the last 90 days. 4.00% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: “EXACT Sciences Co. (EXAS) Shares Sold by Pegasus Partners Ltd.” was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.chaffeybreeze.com/2018/02/15/exact-sciences-co-exas-shares-sold-by-pegasus-partners-ltd.html.
EXACT Sciences Profile
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for EXACT Sciences Co. (NASDAQ:EXAS).
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.